title: VEGFA activates erythropoietin receptor and enhances VEGFR2-mediated pathological angiogenesis.
abstract: Clinical and animal studies implicate erythropoietin (EPO) and EPO receptor (EPOR) signaling in angiogenesis. In the eye, EPO is involved in both physiological and pathological angiogenesis in the retina. We hypothesized that EPOR signaling is important in pathological angiogenesis and tested this hypothesis using a rat model of oxygen-induced retinopathy that is representative of human retinopathy of prematurity. We first determined that EPOR expression and activation were increased and that activated EPOR was localized to retinal vascular endothelial cells (ECs) in retinas at postnatal day 18 (p18), when pathological angiogenesis in the form of intravitreal neovascularization occurred. In human retinal microvascular ECs, EPOR was up-regulated and activated by VEGF. Lentiviral-delivered shRNAs that knocked down Müller cell-expressed VEGF in the retinopathy of prematurity model also reduced phosphorylated EPOR (p-EPOR) and VEGFR2 (p-VEGFR2) in retinal ECs. In human retinal microvascular ECs, VEGFR2-activated EPOR caused an interaction between p-EPOR and p-VEGFR2; knockdown of EPOR by siRNA transfection reduced VEGF-induced EC proliferation in association with reduced p-VEGFR2 and p-STAT3; however, inhibition of VEGFR2 activation by siRNA transfection or semaxanib (SU5416) abolished VEGFA-induced proliferation of ECs and phosphorylation of VEGFR2, EPOR, and STAT3. Our results show that VEGFA-induced p-VEGFR2 activates EPOR and causes an interaction between p-EPOR and p-VEGFR2 to enhance VEGFA-induced EC proliferation by exacerbating STAT3 activation, leading to pathological angiogenesis.
authors.affiliation: The John Moran Eye Center, The University of Utah, Salt Lake City, Utah.
authors.forename: Zhihong
authors.initials: Z
authors.lastname: Yang
authors.affiliation: The John Moran Eye Center, The University of Utah, Salt Lake City, Utah.
authors.forename: Haibo
authors.initials: H
authors.lastname: Wang
authors.affiliation: The John Moran Eye Center, The University of Utah, Salt Lake City, Utah.
authors.forename: Yanchao
authors.initials: Y
authors.lastname: Jiang
authors.affiliation: The John Moran Eye Center, The University of Utah, Salt Lake City, Utah. Electronic address: me.hartnett@hsc.utah.edu.
authors.forename: M Elizabeth
authors.initials: ME
authors.lastname: Hartnett
mesh_terms: D000818:Animals; D015153:Blotting, Western; D004195:Disease Models, Animal; D042783:Endothelial Cells / Q000378:metabolism; D055785:Gene Knockdown Techniques; D006801:Humans; D009389:Neovascularization, Pathologic / Q000378:metabolism*; D010766:Phosphorylation; D034741:RNA, Small Interfering; D051381:Rats; D017207:Rats, Sprague-Dawley; D017467:Receptors, Erythropoietin / Q000378:metabolism*; D012178:Retinopathy of Prematurity / Q000378:metabolism* / Q000473:pathology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015398:Signal Transduction / Q000502:physiology; D014162:Transfection; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000378:metabolism*
chemical_list: D034741:RNA, Small Interfering; D017467:Receptors, Erythropoietin; D042461:Vascular Endothelial Growth Factor A; D040301:Vascular Endothelial Growth Factor Receptor-2